



(51) International Patent Classification:
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/US2022/045989

(22) International Filing Date:
07 October 2022 (07.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/253,509 07 October 2021 (07.10.2021) US

(71) Applicant: **SOMALOGIC OPERATING CO., INC.**
[US/US]; 2945 Wilderness Place, Boulder, Colorado 80301 (US).

(72) Inventors: **ALEXANDER, Leigh**; c/o Somalogic Operating Co., Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US). **PATERSON, Clare**; c/o Somalogic Operating Co., Inc., 2945 Wilderness Place, Boulder, Colorado

80301 (US). **OSTROFF, Rachel M.**; c/o Somalogic Operating Co., Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US). **HAGAR, Yolanda**; c/o Somalogic Operating Co., Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US). **KURESHI, Natasha**; c/o Somalogic Operating Co., Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US).

(74) Agent: **SCARR, Rebecca** et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: LUNG CANCER PREDICTION AND USES THEREOF




FIG. 6

(57) Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for evaluating and predicting lung cancer risk. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to estimate or determine lung cancer risk. In another aspect, methods are provided for evaluating and predicting lung cancer risk in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*